• ChemoCentryx (CCXI) Phase 2 Results of CCX168 for Atypical Hemolytic Uremic Syndrome (aHUS)

       (0 reviews)

    Clinical and Regulatory
    Event Type: Phase 2 Results
    Timing: Q4 2016
    Designation(s): None

    This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Other
    Indication: Atypical Hemolytic Uremic Syndrome (aHUS)
    Lead Indication?: Yes
    Treatment Name: CCX168

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: ChemoCentryx
    Stock Symbol: CCXI
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://ir.chemocentryx.com/releasedetail.cfm?ReleaseID=983493
    Partnership: No

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement



    Anticipated Milestones

    Orphan and Rare Diseases:

    • Evaluate formal feedback from End of Phase II and scientific advice meetings with U.S. and EU regulatory agencies and formalize the CCX168 AAV Phase III development plan in the second half of 2016;
    • Initiate Phase III development program with CCX168 for the treatment of AAV by the end of 2016; and
    • Report early results from the Phase II pilot study of CCX168 in aHUS patients who are on dialysis in late 2016.



      Report Event

    User Feedback

    There are no reviews to display.